The recent coronavirus pandemic underscored how dangerous viral infections can be when they get out of hand. The communicable respiratory disease took nearly 7 million lives, bringing the globe to a standstill as countries shut their borders to prevent infections. In a recent study, researchers tried to determine whether similar viral infections and autoimmune diseases were connected.
Autoimmune conditions occur when an individual’s immune system mistakes healthy tissue for foreign invaders and begins attacking the body. Although we still don’t know the exact cause of autoimmune diseases, scientists have spent decades studying the underlying mechanisms involved in the development of autoimmune diseases to develop more effective ways of treatment.
Roughly 5–8% of the U.S. population is affected by autoimmune conditions including type 1 diabetes, multiple sclerosis (MS) and inflammatory bowel disease (IBD). Scientists posit that the diseases occur due to a mix of genetic and nongenetic factors such as diet, toxic chemicals and pathogens that increase the risk of autoimmunity. Chronic viral infections seem to be a risk factor in autoimmunity, with the recent COVID-19 pandemic being accompanied by a rise in autoimmune disorder cases in patients diagnosed with the coronavirus.
The primary mechanism behind autoimmunity is an immune system with low tolerance to self-antigens, which are antigens that originate from your own cells. This tolerance loss can arise due to altered central tolerance selection. Central tolerance involves several selection processes in the bone marrow and thymus that eliminate autoreactive B- and T-Cells before they enter the blood. Prior studies have revealed that viral infections of the thymus can cause autoimmunity by interrupting the T-cell life cycle.
Peripheral tolerance is the main defense against reactive B- and T- cells that manage to enter the bloodstream by using several immune cells to limit the intensity, duration and location of immune responses. Poor peripheral tolerance functions can lead to autoimmune conditions such as myasthenia gravis, type 1 diabetes and multiple sclerosis. Continued inflammation due to viral infections can also increase one’s risk of autoimmunity.
A protein produced by the SARS-CoV-2 viroporin, hepatitis C and the influenza virus M2 ion channel has been found to activate intracellular components called inflammasomes that lead to inflammatory responses. COVID-19 also causes the overproduction of CD8+ T-cells and mature natural killer cells as well as dysregulation of inflammatory cytokines and B- and T- cells, increasing a patient’s risk of autoimmunity.
This cocktail of changes caused by viral infections such as COVID significantly raises the chances of developing conditions, including polymyalgia rheumatica, mixed connective tissue disease, psoriasis, celiac disease, Sjörgen syndrome and dermatopolymyositis.
Autoimmune conditions are taking an increasing toll on economies and communities, and a number of enterprises, such as Aditxt Inc. (NASDAQ: ADTX), are rising to the challenge by conducting R&D programs aimed at finding ways to reprogram immune systems of individuals with a view to rolling back the malfunctions that trigger autoimmunity.
NOTE TO INVESTORS: The latest news and updates relating to Aditxt Inc. (NASDAQ: ADTX) are available in the company’s newsroom at https://ibn.fm/ADTX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers,…
Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer…
High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix…
Most existing cancer treatments not only attack cancer cells but also adversely impact healthy body cells. The…
LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight…
Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent…